fotemustine has been researched along with Skin Neoplasms in 47 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 19 (40.43) | 18.2507 |
| 2000's | 17 (36.17) | 29.6817 |
| 2010's | 10 (21.28) | 24.3611 |
| 2020's | 1 (2.13) | 2.80 |
| Authors | Studies |
|---|---|
| Franken, MG; Gheorghe, M; Haanen, JBAG; Leeneman, B; Uyl-de Groot, CA; van Baal, PHM | 1 |
| Amato, G; Calabrò, L; Camerini, R; Chiarion-Sileni, V; Covre, A; Cutaia, O; Del Vecchio, M; Di Giacomo, AM; Ferrucci, PF; Giannarelli, D; Guida, M; Guidoboni, M; Maio, M; Mandalà, M; Marchetti, P; Quaglino, P; Valente, M | 1 |
| Bedane, C; Combemale, P; Cupissol, D; Derrey, S; Dygai-Cochet, I; Lamant, L; Leccia, MT; Lubrano, V; Mazeau-Woynar, V; Mirabel, X; Modiano, P; Mourrégot, A; Planchamp, F; Rougé Bugat, ME; Sassolas, B; Siegrist, S; Thariat, J; Tiffet, O; Truc, G; Verdoni, L | 1 |
| Annesi, D; Ascierto, PA; Calabrò, L; Danielli, R; Del Vecchio, M; Di Giacomo, AM; Fonsatti, E; Giannarelli, D; Guidoboni, M; Maccalli, C; Maio, M; Maurichi, A; Orgiano, L; Parmiani, G; Pilla, L; Queirolo, P; Ridolfi, R; Santinami, M; Simeone, E; Spadola, G; Testori, A | 1 |
| Jorda, E; Lopez, V; Marti, N; Monteagudo, C; Pinazo, I | 1 |
| Aitini, E; Ballardini, M; Bichisao, E; Fiorentini, G; Freschi, A; Guida, M; Michiara, M; Ridolfi, L; Ridolfi, R | 1 |
| Bonnet, PA; Bressolle, FM; Cooper, JF; Deleuze-Masquéfa, C; Gattacceca, F; Khier, S; Margout, D; Moarbess, G; Pinguet, F; Solassol, I | 1 |
| Anichini, A; Bajetta, E; Bedognetti, D; Canova, S; Del Vecchio, M; Di Guardo, L; Morosini, P; Mortarini, R; Perrone, T; Pimpinelli, N; Queirolo, P; Sertoli, MR | 1 |
| Dréno, B; Quéreux, G | 1 |
| Auffret, M; Bertrand, M; Gauthier, S; Mortier, L; Wémeau-Stervinou, L | 1 |
| Brocard, L; Daste, A; Durando, X; Gimbergues, P; Magné, N; Mansard, S; Thivat, E | 1 |
| Annesi, D; Ascierto, PA; Di Giacomo, AM; Ferrucci, PF; Fonsatti, E; Giannarelli, D; Maio, M; Marasco, A; Nicoletti, SV; Parmiani, G; Pilla, L; Queirolo, P; Ridolfi, R; Rivoltini, L; Santinami, M; Simeone, E; Testori, A | 1 |
| Garbe, C | 1 |
| Foletto, M; Lise, M; Mocellin, S; Pilati, P; Rossi, CR | 1 |
| Bensadoun, RJ; Bonneterre, ME; Bourdin, S; Bui, BN; Clavel, M; Cupissol, D; De Gislain, C; Delaunay, MM; Guillot, B; Hauschild, A; Lesimple, T; Mohr, P; Mornex, F; Mousseau, M; Thomas, L; Tilgen, W; Ulrich, J | 1 |
| Dréno, B; Wallon-Dumont, G | 1 |
| Binder, B; Cerroni, L; Kerl, H; Richtig, E; Smolle, J; Wolf, IH | 1 |
| De Salvo, GL; Foletto, M; Lejeune, FJ; Lise, M; Lopes, M; Mocellin, S; Pilati, PL; Pontes, L; Ribeiro, M; Rossi, CR | 1 |
| Aamdal, S; Avril, MF; Bieber, T; Bonerandi, JJ; Bonneterre, J; Fra, J; Gilde, K; Gonzalez Larriba, JL; Grob, JJ; Guillem Porta, V; Hauschild, A; Kamanabrou, D; Menu, Y; Mohr, P; Neuber, K; Pehamberger, H; Saïag, P; Scherrer, A; Sufliarsky, J; Weichenthal, M | 1 |
| Eigentler, TK; Garbe, C | 1 |
| Bonenkamp, JJ; de Faria Lima, R; de Wilt, JH; Doubrovsky, A; Kam, PC; Thompson, JF | 1 |
| Karpenko, LG | 1 |
| Akimov, MA; Bogdanova, NV; Gershanovich, ML; Konstantinova, MM; Nosov, DA | 1 |
| Clerico, MA; Marinozzi, C; Sozzi, P; Turrisi, G | 1 |
| Bembenek, A; Hauschild, A; Kähler, KC; Kettelhack, C; Schlag, PM; Siegel, R | 1 |
| Avril, MF | 1 |
| Algermissen, B; Czarnetzki, BM; Kohlmus, CM; Schadendorf, D; Worm, M | 1 |
| Bureau, B; Célérier, P; Dreno, B; Litoux, P | 1 |
| Benoit, F; Bertheas, MF; Cambazard, F; Graille, MC; Guy, C; Lanthier, K; Perrot, JL | 1 |
| Anderson, CM; Buzaid, AC; Legha, SS | 1 |
| Azevedo, MC; Lopes, M; Pontes, L; Ribeiro, M; Santos, JG | 1 |
| Bartley, J; Hayes, MT; Parsons, PG | 1 |
| Breitbart, E; Makki, A; Mohr, P; Schadendorf, D | 1 |
| Bassères, N; Bizzari, JP; Bonerandi, JJ; Gérard, B; Grob, JJ; Richard, MA; Zarrour, H | 1 |
| Bröcker, EB; Göring, HD; Kämpgen, E; Kröning, Y; Trebing, D; Zierner, A | 1 |
| Aamdal, S; Bohmann, T; Gerard, B; Lucas, C; Semb, KA | 1 |
| Ablett, E; Dannoy, PA; Parsons, PG; Pedley, J; Sturm, RA | 1 |
| Binder, M; Pehamberger, H; Seeber, A; Steiner, A; Wolff, K | 1 |
| Becker, JC; Bröcker, EB; Kämpgen, E; Terheyden, P | 1 |
| Bock, M; Deichmann, M; Jäckel, A; Näher, H; Waldmann, V | 1 |
| Chaitchik, S; Gerard, B; Inbar, M; Merimsky, O | 1 |
| Avril, MF; Bonneterre, J; Cupissol, D; Fargeot, P; Fumoleau, P; Grob, JJ; Israel, L; Kalis, B; Kerbrat, P; Lambert, D | 1 |
| Binder, M; Dorffner, R; Glebowski, E; Pehamberger, H; Winkler, A; Wolff, K | 1 |
| Berger, J; Brassow, FW; Breitbart, EW; Schallreuter, KU; Teichmann, W; Wenzel, E | 1 |
| Breitbart, EW; Mensing, H; Schallreuter, KU; Wood, JM | 1 |
| Aapro, M; Ardizzoni, A; Becquart, D; Calabresi, F; Dirix, L; Gerard, B; Wils, J | 1 |
8 review(s) available for fotemustine and Skin Neoplasms
| Article | Year |
|---|---|
A systematic literature review and network meta-analysis of effectiveness and safety outcomes in advanced melanoma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azetidines; Benzimidazoles; Cancer Vaccines; Carboplatin; Dacarbazine; gp100 Melanoma Antigen; Humans; Hydrazines; Imidazoles; Interleukin-2; Ipilimumab; Lenalidomide; Melanoma; Network Meta-Analysis; Nitrosourea Compounds; Nivolumab; Organophosphorus Compounds; Oximes; Paclitaxel; Piperidines; Progression-Free Survival; Proportional Hazards Models; Pyridones; Pyrimidinones; Skin Neoplasms; Sorafenib; Survival Rate; Temozolomide; Treatment Outcome; Vemurafenib | 2019 |
Fotemustine for the treatment of melanoma.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Humans; Melanoma; Molecular Structure; Nitrosourea Compounds; Organophosphorus Compounds; Skin Neoplasms; Treatment Outcome | 2011 |
[Therapeutic strategies and systemic treatment of brain melanoma metastases].
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Humans; Immunotherapy; Indoles; Ipilimumab; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds; Palliative Care; Radiosurgery; Radiotherapy; Skin Neoplasms; Sulfonamides; Temozolomide; Vemurafenib | 2013 |
Isolated limb perfusion in locally advanced cutaneous melanoma.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Perfusion; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Genetic Therapy; Humans; Melanoma; Melphalan; Neoplasm Staging; Nitrosourea Compounds; Organophosphorus Compounds; Pilot Projects; Remission Induction; Reproducibility of Results; Skin Neoplasms; Tumor Necrosis Factor-alpha | 2002 |
[Treatment of melanoma].
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cell- and Tissue-Based Therapy; Cells, Cultured; Chemotherapy, Adjuvant; Clinical Trials as Topic; Dacarbazine; Drug Therapy, Combination; Forecasting; Humans; Immunization, Passive; Immunotherapy; Immunotherapy, Active; Interferon-alpha; Interleukin-2; Lymph Node Excision; Lymphatic Metastasis; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds; Skin Neoplasms; T-Lymphocytes, Cytotoxic; Temozolomide; Time Factors | 2003 |
[Therapy of malignant melanoma at the stage of distant metastasis].
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dacarbazine; Disease Progression; Humans; Immunotherapy; Interferon-alpha; Interleukin-2; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Melanoma; Neoplasm Metastasis; Nitrosourea Compounds; Organophosphorus Compounds; Palliative Care; Prognosis; Radiotherapy Dosage; Randomized Controlled Trials as Topic; Skin Neoplasms; Temozolomide; Time Factors; Tomography, X-Ray Computed; Vindesine | 2004 |
Systemic treatments for advanced cutaneous melanoma.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Dacarbazine; Humans; Immunotherapy, Active; Interferon-alpha; Interleukin-2; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds; Remission Induction; Skin Neoplasms; Survival Rate; Temozolomide | 1995 |
[Therapy of metastatic malignant uveal melanoma].
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemoembolization, Therapeutic; Female; Follow-Up Studies; Humans; Liver Neoplasms; Lung Neoplasms; Male; Melanoma; Middle Aged; Multicenter Studies as Topic; Neoplasm Metastasis; Nitrosourea Compounds; Organophosphorus Compounds; Prognosis; Skin Neoplasms; Time Factors; Uveal Neoplasms | 2001 |
17 trial(s) available for fotemustine and Skin Neoplasms
| Article | Year |
|---|---|
Primary Analysis and 4-Year Follow-Up of the Phase III NIBIT-M2 Trial in Melanoma Patients With Brain Metastases.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Female; Follow-Up Studies; Humans; Ipilimumab; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Nivolumab; Organophosphorus Compounds; Skin Neoplasms; Survival Rate; Time Factors; Young Adult | 2021 |
Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Biological Therapy; Brain Neoplasms; Female; Follow-Up Studies; Humans; Ipilimumab; Male; Melanoma; Middle Aged; Neoplasm Staging; Nitrosourea Compounds; Organophosphorus Compounds; Prognosis; Skin Neoplasms; Survival Rate | 2015 |
Multicentre, open, noncomparative Phase II trial to evaluate the efficacy and tolerability of fotemustine, cisplatin, alpha-interferon and interleukin-2 in advanced melanoma patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Combined Modality Therapy; Disease Progression; Female; Humans; Immunologic Factors; Immunotherapy; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Salvage Therapy; Skin Neoplasms; Survival Analysis | 2009 |
Bevacizumab plus fotemustine as first-line treatment in metastatic melanoma patients: clinical activity and modulation of angiogenesis and lymphangiogenesis factors.
Topics: Adult; Aged; Angiogenic Proteins; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Cells, Cultured; Female; Humans; Lymphangiogenesis; Male; Melanoma; Middle Aged; Neoadjuvant Therapy; Nitrosourea Compounds; Organophosphorus Compounds; Skin Neoplasms; Treatment Outcome; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor C; Young Adult | 2010 |
Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Disease-Free Survival; Female; Hematologic Diseases; Humans; Ipilimumab; Male; Melanoma; Middle Aged; Neoplasm Grading; Neoplasm Staging; Nitrosourea Compounds; Organophosphorus Compounds; Skin Neoplasms | 2012 |
A prospective randomized multicentre phase III trial of fotemustine plus whole brain irradiation versus fotemustine alone in cerebral metastases of malignant melanoma.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Cranial Irradiation; Disease Progression; Disease-Free Survival; Female; Humans; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Prospective Studies; Skin Neoplasms; Survival Rate; Treatment Outcome | 2003 |
Phase I-II study on isolation antiblastic fotemustine perfusion after dacarbazine chemosensitization for advanced melanoma of the extremities.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Perfusion; Dacarbazine; Extremities; Female; Humans; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Skin Neoplasms; Treatment Outcome | 2003 |
Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Europe; Female; Humans; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Quality of Life; Skin Neoplasms; Statistics, Nonparametric; Survival Analysis | 2004 |
[Effectiveness and safety of combined mustoforan, cisplatin and tamoxifen for disseminated cutaneous melanoma (results of the IC4-10036-46-RU trial)].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Female; Humans; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Skin Neoplasms; Tamoxifen; Treatment Outcome | 2005 |
Hepatic arterial Fotemustine chemotherapy in patients with liver metastases from cutaneous melanoma is as effective as in ocular melanoma.
Topics: Adult; Aged; Antineoplastic Agents; Eye Neoplasms; Female; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Skin Neoplasms; Survival Analysis | 2007 |
Isolated limb perfusion with fotemustine after chemosensitization with dacarbazine in melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Arm; Chemotherapy, Cancer, Regional Perfusion; Dacarbazine; Female; Humans; Leg; Male; Melanoma; Middle Aged; Neoplasm Staging; Nitrosourea Compounds; Organophosphorus Compounds; Pilot Projects; Skin Neoplasms | 1997 |
Combined treatment of stage IV melanoma patients with amifostine and fotemustine--a pilot study.
Topics: Amifostine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Brain Neoplasms; Drug Administration Schedule; Humans; Leukopenia; Melanoma; Neoplasm Staging; Nitrosourea Compounds; Organophosphorus Compounds; Pilot Projects; Skin Neoplasms; Thrombocytopenia | 1998 |
Combined treatment with dacarbazine, cisplatin, fotemustine and tamoxifen in metastatic malignant melanoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Dacarbazine; Humans; Melanoma; Middle Aged; Neoplasm Metastasis; Nitrosourea Compounds; Organophosphorus Compounds; Skin Neoplasms; Survival Rate; Tamoxifen | 1998 |
Clinical experience of fotemustine, cisplatin and high dose tamoxifen in patients with metastatic malignant melanoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Humans; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Skin Neoplasms; Tamoxifen; Time Factors | 1998 |
Sequential interferon-alpha2b, interleukin-2 and fotemustine for patients with metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Disease-Free Survival; Female; Humans; Interferon alpha-2; Interferon-alpha; Interleukin-2; Lung Neoplasms; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Recombinant Proteins; Skin Neoplasms; Survival Rate | 2000 |
Fotemustine--an advance in the treatment of metastatic malignant melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Skin Neoplasms | 1992 |
Multicenter phase II trial of the single agent fotemustine in patients with advanced malignant melanoma.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Drug Evaluation; Europe; Female; Humans; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Skin Neoplasms | 1991 |
22 other study(ies) available for fotemustine and Skin Neoplasms
| Article | Year |
|---|---|
[Management of patients with metastatic cutaneous melanoma: French national guidelines. French National Cancer Institute].
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Bone Neoplasms; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease Management; France; Humans; Indoles; Ipilimumab; Liver Neoplasms; Lung Neoplasms; Melanoma; Molecular Targeted Therapy; Neoplasm Staging; Nitrosourea Compounds; Oncogenes; Organophosphorus Compounds; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Sulfonamides; Temozolomide; Vemurafenib | 2014 |
Follicular hyperplasia on the face subsequent to therapy with sorafenib. A new skin side effect.
Topics: Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Humans; Hyperplasia; Lung Neoplasms; Male; Melanoma; Niacinamide; Nitrosourea Compounds; Organophosphorus Compounds; Phenylurea Compounds; Pyridines; Skin; Skin Diseases; Skin Neoplasms; Sorafenib | 2009 |
Pharmacology of EAPB0203, a novel imidazo[1,2-a]quinoxaline derivative with anti-tumoral activity on melanoma.
Topics: Aminoquinolines; Animals; Antineoplastic Agents; Cell Line, Tumor; Dose-Response Relationship, Drug; Humans; Imidazoles; Imiquimod; Injections, Intraperitoneal; Injections, Intravenous; Male; Melanoma; Mice; Mice, Nude; Nitrosourea Compounds; Organophosphorus Compounds; Quinoxalines; Rats; Skin Neoplasms; Xenograft Model Antitumor Assays | 2010 |
[New toxicity of fotemustine: diffuse interstitial lung disease].
Topics: Aged, 80 and over; Antineoplastic Agents; Humans; Lung Diseases, Interstitial; Male; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds; Skin Neoplasms | 2012 |
Ipilimumab with fotemustine in metastatic melanoma.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Female; Humans; Ipilimumab; Male; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds; Skin Neoplasms | 2012 |
Topical imiquimod in the treatment of metastatic melanoma to skin.
Topics: Adjuvants, Immunologic; Administration, Cutaneous; Aged; Aged, 80 and over; Aminoquinolines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Dacarbazine; Female; Humans; Imiquimod; Interferon alpha-2; Interferon-alpha; Knee; Leg; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Neoplasm Recurrence, Local; Nitrosourea Compounds; Organophosphorus Compounds; Recombinant Proteins; Scalp; Skin Neoplasms; Treatment Outcome | 2003 |
Isolated limb infusion with fotemustine after dacarbazine chemosensitisation for inoperable loco-regional melanoma recurrence.
Topics: Aged; Aged, 80 and over; Amputation, Surgical; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Chemotherapy, Cancer, Regional Perfusion; Dacarbazine; Follow-Up Studies; Humans; Limb Salvage; Lower Extremity; Melanoma; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Nitrosourea Compounds; Organophosphorus Compounds; Remission Induction; Salvage Therapy; Skin Neoplasms; Treatment Outcome | 2004 |
[Experience with use of mustoforan at the Clinical Oncological Dispensary of the Republic of Tatarstan].
Topics: Antineoplastic Agents; Cancer Care Facilities; Disease Progression; Humans; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds; Retrospective Studies; Russia; Skin Neoplasms; Treatment Outcome | 2005 |
Persistent thrombocytopenia during melanoma treatment with fotemustine.
Topics: Aged; Antineoplastic Agents; Humans; Male; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds; Skin Neoplasms; Thrombocytopenia | 2006 |
[Fotemustine: muphoran].
Topics: Antineoplastic Agents; Humans; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds; Skin Neoplasms | 2007 |
Chemosensitivity testing of human malignant melanoma. A retrospective analysis of clinical response and in vitro drug sensitivity.
Topics: Antineoplastic Agents; Bleomycin; Carboplatin; Carmustine; Cisplatin; Dacarbazine; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance; Drug Screening Assays, Antitumor; Fluorouracil; Forecasting; Humans; In Vitro Techniques; Lymphatic Metastasis; Melanoma; Methotrexate; Nitrosourea Compounds; Organophosphorus Compounds; Pilot Projects; Remission Induction; Retrospective Studies; Skin Neoplasms; Tumor Cells, Cultured; Vindesine | 1994 |
[Combination of fotemustine-dacarbazine and interferon alpha in the treatment of metastatic malignant melanoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Humans; Interferon-alpha; Karnofsky Performance Status; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Nitrosourea Compounds; Organophosphorus Compounds; Skin Neoplasms; Treatment Outcome | 1993 |
[Acquired myelodysplastic syndromes after treatment of melanoma with fotemustine and dacarbazine].
Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Drug Therapy, Combination; Fatal Outcome; Female; Humans; Melanoma; Middle Aged; Myelodysplastic Syndromes; Nitrosourea Compounds; Organophosphorus Compounds; Skin Neoplasms | 1995 |
In vitro evaluation of fotemustine as a potential agent for limb perfusion in melanoma.
Topics: Adenoviridae; Antineoplastic Agents; Carcinogens; Cell Cycle; Cell Survival; DNA, Neoplasm; Drug Evaluation; Humans; Hyperthermia, Induced; Melanoma; Methylnitronitrosoguanidine; Nitrosourea Compounds; O(6)-Methylguanine-DNA Methyltransferase; Organophosphorus Compounds; Perfusion; Skin Neoplasms; Tumor Cells, Cultured; Virus Replication | 1998 |
Effective combined immunochemotherapy with dinitrochlorobenzene and fotemustine in skin and brain metastases of melanoma.
Topics: Allergens; Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Dermatitis, Allergic Contact; Dinitrochlorobenzene; Humans; Immunotherapy; Irritants; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Remission Induction; Salvage Therapy; Skin Neoplasms | 1998 |
UVB-specific regulation of gene expression in human melanocytic cells: cell cycle effects and implication in the generation of melanoma.
Topics: Antineoplastic Agents; beta-Galactosidase; Cell Cycle; Cisplatin; Demecolcine; Genes, fos; Genes, p53; HeLa Cells; HIV Long Terminal Repeat; Humans; Hydroxyurea; Inosine; Melanocytes; Melanoma; Methylnitronitrosoguanidine; Neoplasms, Radiation-Induced; Nitrosourea Compounds; Organophosphorus Compounds; Proto-Oncogene Proteins c-fos; Recombinant Proteins; Skin Neoplasms; Tetradecanoylphorbol Acetate; Transfection; Tumor Cells, Cultured; Ultraviolet Rays | 1998 |
Treatment of metastatic malignant melanoma with dacarbazine plus fotemustine.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Skin Neoplasms; Treatment Outcome | 1998 |
Fotemustine plus dacarbazine for malignant melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Drug Evaluation; Female; Humans; Leukopenia; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Skin Neoplasms; Thrombocytopenia | 1992 |
Fotemustine plus dacarbazine in advanced stage III malignant melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Humans; Leukopenia; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Nitrosourea Compounds; Organophosphorus Compounds; Skin Neoplasms; Thrombocytopenia | 1992 |
Positive phase II study in the treatment of advanced malignant melanoma with fotemustine.
Topics: Adult; Aged; Antineoplastic Agents; Drug Evaluation; Female; Humans; Infusions, Intravenous; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Nitrosourea Compounds; Organophosphorus Compounds; Skin Neoplasms; Time Factors | 1991 |
Local treatment of cutaneous and subcutaneous metastatic malignant melanoma with fotemustine.
Topics: Adult; Aged; Antineoplastic Agents; Female; Humans; Injections, Intralesional; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Skin Neoplasms | 1991 |
[Fotemustine in the treatment of metastatic malignant melanoma. Overall analysis of results].
Topics: Antineoplastic Agents; Dacarbazine; Drug Synergism; Drug Therapy, Combination; Humans; Melanoma; Neoplasm Metastasis; Nitrosourea Compounds; Organophosphorus Compounds; Skin Neoplasms | 1990 |